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Abstract
Background: MicroRNA-34a (miR-34a) is a transcriptional target of p53 and is down-regulated in pancreatic cancer. This
study aimed to investigate the functional significance of miR-34a in pancreatic cancer progression through its epigenetic
restoration with chromatin modulators, demethylating agent 5-Aza-29-deoxycytidine (5-Aza-dC) and HDAC inhibitor
Vorinostat (SAHA).
Methodology/Principal Findings: Re-expression of miR-34a in human pancreatic cancer stem cells (CSCs) and in human
pancreatic cancer cell lines upon treatment with 5-Aza-dC and SAHA strongly inhibited the cell proliferation, cell cycle
progression, self-renewal, epithelial to mesenchymal transition (EMT) and invasion. In pancreatic CSCs, modulation of miR-
34a induced apoptosis by activating caspase-3/7. Treatment of pancreatic CSCs with the chromatin-modulating agents
resulted in the inhibition of Bcl-2, CDK6 and SIRT1, which are the putative targets of miR-34a. MiR-34a upregulation by these
agents also induced acetylated p53, p21
WAF1, p27
KIP1 and PUMA in pancreatic CSCs. Inhibition of miR-34a by antagomiR
abrogates the effects of 5-Aza-dC and SAHA, suggesting that 5-Aza-dC and SAHA regulate stem cell characteristics through
miR-34a. In CSCs, SAHA inhibited Notch pathway, suggesting its suppression may contribute to inhibition of the self-
renewal capacity and induction of apoptosis. Interestingly, treatment of pancreatic CSCs with SAHA resulted in the
inhibition of EMT with the transcriptional up-regulation of E-Cadherin and down-regulation of N-Cadherin. Expression of
EMT inducers (Zeb-1, Snail and Slug) was inhibited in CSCs upon treatment with SAHA. 5-Aza-dC and SAHA also retard in
vitro migration and invasion of CSCs.
Conclusions: The present study thus demonstrates the role of miR-34a as a critical regulator of pancreatic cancer
progression by the regulating CSC characteristics. The restoration of its expression by 5-Aza-dC and SAHA in CSCs will not
only provide mechanistic insight and therapeutic targets for pancreatic cancer but also promising reagents to boost patient
response to existing chemotherapies or as a standalone cancer drug by eliminating the CSC characteristics.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer death in
United States and is a devastating invasive disease and one of the
most aggressive cancers [1]. The poor prognosis of pancreatic
adenocarcinoma is attributed to its late presentation, lack of
accurate biomarkers for early diagnosis for the possibility of
curative resection as well as the propensity of early metastasis.
Therefore, novel diagnostic modalities for early diagnosis and new
therapeutic strategies are urgently needed.
MicroRNAs (miRNAs) are endogenous, noncoding small RNAs
19–25 nucleotides in length, which are now recognized as crucial
post transcriptional regulators of gene expression [2,3,4]. The
ability of miRNAs to regulate multiple genes conform them to play
important roles in biological processes that effect tumor progres-
sion including migration, invasion, epithelial to mesenchymal
transition (EMT) and metastasis [5,6,7,8,9,10]. MiRNAs are very
promising as early biomarkers, prognostic indicators and mech-
anism based therapeutic targets for anticancer treatments
[11,12,13,14,15] because their aberrant expressions are linked to
cancer stem cell (CSC) deregulation and thus oncogenesis [16].
Cancer stem cells give rise to the tumor bulk through
continuous self-renewal and differentiation [17]. Pancreatic CSCs
are highly tumorigenic and self renewing sub-population that
express the cell surface marker CD133+/CD44+/CD24+/ESA+
[17,18,19]. Strategies are being developed towards the targeted
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ical stem cells, which may lead to marked improvement in patient
outcome. By altering the expression of specific miRNAs that may
play an important role in pancreatic CSC renewal and may thus
contribute to the development of pancreatic carcinoma, would
help achieve a selective and targeted elimination of the pancreatic
CSCs. Therefore, understanding the mechanisms that regulate
self-renewal is of greatest importance for discovery of anticancer
drugs targeting CSCs.
TP53 is an important tumor suppressor gene whose biological
effects are largely due to its function as a transcriptional regulator
[20]. TP53 mutations are relatively common and occur in up to
70% of cases with pancreatic adenocarcinoma and are most
commonly seen in poorly differentiated tumors [21,22,23,24,25].
The tumor suppressor TP53 has been identified as a transcrip-
tional regulator of miR-34a and several recent studies have
implicated the miR-34 family of miRNAs in the p53 tumor
suppressor network [20,26]. miR-34a is highly expressed in
normal tissues, like testis, lung, adrenal gland and spleen, although
its physiological function is unknown. miR-34a is localized on
human chromosome 1p36, which is a region associated with a
variety of cancers, and has been shown to be down-regulated in
pancreatic cancer [20]. Reduced expression of miR-34a in
pancreatic cancer could be a resultant of either transcriptional
regulation due to p53 mutations as these are very frequent [22] or
through epigenetic silencing. Therefore, understanding the
contributions of these mechanisms in the down regulation of
miR-34a in pancreatic cancer, which may contribute to the
malignancy of the pancreas, could be of relevance.
MiR-34a acts as a suppressor of neuroblastoma tumorigenesis
by targeting the mRNA encoding E2F3 and reducing E2F3
protein levels [27]. It has also been shown to be hyper-methylated
in breast, ovarian, colon, lung and haematological malignancies
and downregulate CDK6 translation thereby demonstrating the
tumor suppressor role of miR-34a [28,29,30]. The miR-34a
responsive genes are highly enriched for those that regulate cell-
cycle progression, cellular proliferation, apoptosis, DNA repair,
and angiogenesis thereby providing a functional basis for the
epigenetic inactivation of this miRNA in pancreatic cancer [31].
It is well established that many tumor suppressor genes in human
cancers are silenced by promoter methylation accompanied by
chromatin alterations due to recruitment of histone deactylases by
proteins binding to methylated CpG-residues. These epigenetic
markersassociatedwiththesilencingoftumorsuppressorgenesmay
contribute in the tumor progression and can be therapeutically
reversible, serving as targets for pancreatic cancer treatment. Based
on this premise, we quantified the expression of miR-34a in human
pancreatic CSCs and pancreatic cancer cell lines irrespective of the
p53 mutation status, compared to normal pancreatic ductal
epithelial cells using TaqMan miRNA assays.
Notch signals are known to affect stem cell selfrenewal and
differentiation, and have been suggested to play a role during
pancreatic carcinogenesis [32,33]. Several members of the Notch
signaling pathway are expressed in the pancreas [32]. The Notch
receptors are activated by Delta and Serrate/Jagged ligands [34],
which promote proteolytic cleavage and the release of the Notch
intracellular domain (ICD). The activated Notch-ICD translocates
into the nucleus and interacts with the transcription factor CSL/
RBP-Jk and the co-activator Mastermind (MAM) to activate
target genes such as Hes1 and Hes5 [35,36], and Hes expression
can therefore be used as a read out for Notch activity [37].
Our present studies have revealed that expression levels of miR-
34a were significantly reduced in pancreatic CSCs and pancreatic
cancer tumor cells independent of their p53 mutational status,
compared to normal pancreatic ductal epithelial cells. This lead us
to hypothesize that miR-34a, thus may be epigenetically silenced
in pancreatic cancer. Reduction of miR-34a gene methylation and
altered acetylation pattern by the use of chromatin-modifying
agents resulted in concomitant reactivation of miR-34a expression.
Expression of miR-34a in pancreatic CSCs and cell lines was
significantly induced on treatment with chromatin modifiers,
demethylating agent 5-aza-29-deoxycytidine (5-Aza-dC) or the
histone deacetylase inhibitor, SAHA (vorionostat). 5-Aza-dC and
SAHA also inhibited the growth and induced apoptosis in
pancreatic CSCs. Further, to understand the functional role of
miR-34a in the regulation of pancreatic cancer progression the
effect of 5-Aza-dC and SAHA on the protein expression of
putative targets of miR-34a in pancreatic CSCs was examined. 5-
Aza-dC inhibited the expression of cyclin D1 and CDK4 and on
the contrary induced the expression of p27
/KIP1, and these effects
were abrogated in the presence of miR34a antagonist. Similarly,
SAHA down-regulated the expression of SIRT1, cyclin D1,
survivin, Bcl-2, VEGF and CDK6, and up-regulated the
expression of p21 and PUMA in a dose-dependent manner.
Further, treatment of pancreatic CSCs with the chromatin
modifiers resulted in the inhibition of self-renewal, EMT,
migration and invasion of pancreatic CSCs in vitro. Modulation
of the expression of miR-34a by SAHA inhibited the mRNA
expression of various components of the Notch pathway, thus
suggesting that miR-34a may be involved in pancreatic CSC self-
renewal. Zeb-1, Snail and Slug transcriptional expression was
significantly decreased in human pancreatic CSCs and pancreatic
cancer cell lines upon treatment with SAHA. Our results
demonstrate that miR-34a might play an important role in the
regulation of pancreatic tumorigenesis. This is thus far, the first
demonstration of inhibition of pancreatic CSC characteristics by
epigenetic modulation of miR-34a by therapeutic intervention
using 5-Aza-dC and SAHA. Therefore, restoration of miR-34a
expression by 5-Aza-dC and SAHA in pancreatic CSCs will
provide not only unique tools for the investigation of miRNA
function, but also promising reagent to boost patient response to
existing chemotherapies or as standalone cancer drug.
Results
Expression and restoration miR-34a in pancreatic CSCs
and cell lines
We first measured the expression of miR-34a in human
pancreatic CSCs derived from primary tumors and pancreatic
cancer cell lines [ASPC-1 (p53wt) and MiaPaCa-2 (p53mutant)]
and compared with normal pancreatic ductal epithelial cells using
quantitative reverse transcriptase polymerase chain reaction (RT-
PCR-Taqman) and Taqman Real Time Assays. The comparative
Ct (DDCt) method was used to determine the expression fold
change of miR-34a in pancreatic cancer cells compared to normal
pancreatic epithelial cells. Total RNA input was normalized based
on the Ct values obtained for RNU48 used as endogenous control.
Consistent with previous studies in pancreatic cancer [20], we
observed a global decrease in the expression of miR-34a in
pancreatic CSCs and cell lines independent of their p53
mutational status relative to non-neoplastic pancreatic epithelial
cells (Fig. 1A).
Mir-34a is closely associated with a large CpG island suggesting
that it may be epigenetically silenced in pancreatic cancer. To
prove this hypothesis, we examined if the reduced expression of
miR-34a in pancreatic cancer could be restored upon treatment
with a DNA methylation inhibitor, 5-Aza-dc and/or a histone
deacetylase inhibitor, SAHA. Interestingly, miR-34a expression in
miR34a Inhibits Pancreatic Cancer Stem Cells
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MiaPaCa-2] increased significantly following treatment with these
chromatin-modifiers compared with mock treated controls, as
measured by qRT-PCR (Fig. 1B) using Taqman Real Time Assays
using comparative Ct (DDCt) method. Total RNA input was
normalized based on the Ct values obtained for RNU48. These
results demonstrate that 5-Aza-dC and SAHA induces the
restoration of miR-34a in pancreatic cancer cells. The data also
suggest that epigenetic modification of regulatory sequences in
CpG islands and deacetylation of histones may contribute to miR-
34a silencing in pancreatic cancer. Further inhibition of miR-34a
by antgomiR abrogates the effects of 5-Aza-dC and SAHA in
restoration of the expression of miR-34a in pancreatic CSCs
suggesting that 5-Aza-dC and SAHA regulate the stem cell
characteristic through miR-34a (Fig. 1C).
We next examined the transcriptional regulation of miR-34a in
CSCs by miR-34a-luciferase reporter assay (Fig. 1D). SAHA and
5-Aza-dC induced miR-34a-luciferase activity, suggesting a
functional role of miR34a in pancreatic CSCs.
Upregulation of miR-34a inhibits cell proliferation, and
induces apoptosis and cell cycle arrest in human
pancreatic CSCs
We investigated the effect of 5-Aza-dC and SAHA on the
proliferation of pancreatic CSCs by trypan blue staining. 5-Aza-
dC and SAHA significantly inhibited cell proliferation in a dose-
dependent manner in pancreatic CSCs (Fig. 2A). Further, we
examined the effects of these chromatin modulators on the
induction of apoptosis and caspase-3/7 activity in pancreatic
CSCs by annexin-V and PI staining, and caspase-3/7 activity
assay kit, respectively. 5-Aza-dC and SAHA induced apoptosis in
CSCs in a dose-dependent manner which was associated with
increased caspase-3/7 activity (Fig. 2B and C).
Figure 1. Restoration of the expression of miR-34a in pancreatic cancer cells. (A) Relative expression of miR-34a was quantified in human
pancreatic cancer cell lines ASPC-1(p53wt), MiaPACA-2 (p53mutant), human pancreatic cancer stem cells (PanCSC) and human pancreatic normal
ductal epithelial cells (HPNE). (B) Restoration of miR34a by SAHA and Aza-5dC. Pancreatic cancer cell lines ASPC-1(p53wt), MiaPACA-2 (p53mutant)
and pancreatic cancer stem cells were treated with SAHA (3 mM) or Aza-5dC (4 mM) for 24 h. The expression of miR-34a was quantified using
quantitative reverse transcriptase polymerase chain reaction (RT-PCR-Taqman) and Taqman Real Time Assays, and normalized to RNU48 expression.
Data represent mean 6 SD. * = significantly different from control, P,0.05. (C), Anti-miR34a inhibits the ability of SAHA and Aza-5dC to restore
miR34a. Pancreatic CSCs were transiently transfected with either negative control (scrambled) or anti-miR34a oligonucleotide, and treated with SAHA
(3 mM) or Aza-5dC (4 mM) for 24 h. RNA was extracted to measure the expression of miR34a by q-RT-PCR as described above. NC = negative control.
(D), miR34a-Luciferase reporter activity. Pancreatic CSCs were transfected with either negative control (scrambled) or anti-miR34a oligonucleotides
along with miR34a-Luc construct, and treated with either SAHA (1 mM) or Aza-5dC (2 mM) for 24 h. Luciferase activity was measured as per
manufacturer’s instructions (Promega). Data represent mean 6 SD. * = significantly different from control, P,0.05.
doi:10.1371/journal.pone.0024099.g001
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restoration of miR-34a, ASPC-1 cells were treated with or without
SAHA and its effects on the cell cycle distribution was examined
by PI staining using flow cytometry (data not shown). SAHA
induced growth arrest in in G2/M phase of the cell cycle at 24 h
in AsPC-1 cells. Furthermore, SAHA induced G2/M arrest was
abrogated in the presence of miR-34a antagonist relative to the
negative control oligonucleotides thus suggesting the involvement
of miR-34a in the cell cycle arrest by SAHA (data not shown).
Effect of 5-Aza-dC and SAHA on the putative targets of
the miR-34a in pancreatic CSCs
Since miR-34a is involved in the self renewing capacity and
metastasis of pancreatic CSCs, expression of putative targets of
miR-34a in pancreatic CSCs on treatment with 5-Aza-dC and
SAHA was examined by Western blot analysis (Fig. 3A and B).
Our results indicate that 5-Aza-dC and SAHA modulate the
protein expression levels of known direct target genes of miR-34a.
Interestingly, SAHA inhibited the expression of Cyclin D1 and
CDK6 and up regulated the expression of p21/CIP1 in pancreatic
CSCs (Fig. 3A). SAHA also inhibited the expression of SIRT1,
survivin, Bcl-2, VEGF, and induced the expression of acetylated
p53 and PUMA in a dose-dependent manner. Similarly, 5-Aza-dC
inhibited the expression of Notch3, CDK6, survivin and Bcl-2,
and induced the expression of p21/CIP1 and PUMA in a dose-
dependent manner. Since SAHA inhibited the expression of
SIRT1 through up-regulation of miR34a, we next examined the
effects of SAHA on SIRT1 39UTR-luciferase reporter activity.
SAHA inhibited the SIRT1 39UTR-Luciferase activity in a dose-
dependent manner (Fig. 3C). By comparison, SAHA had no effect
on SIRT1 mutant 39UTR-luciferase activity (containing no
functional miR34a binding site). These data suggest that MiR-
34a inhibits SIRT1 expression through a miR-34a-binding site
within the 39 UTR of SIRT1.
Furthermore, manipulating the expression of miR-34a by using
miR-34a antagomiR altered the protein expression of its target
genes (Fig. 4A and B). 5-Aza-dC and SAHA inhibits the expression
of cell cycle regulatory proteins (Cyclin D1 and CDK2) and
VEGF, and up regulates the expression of p27/KIP1 in pancreatic
CSCs. Transfection with antagomiR for miR-34a was alone
sufficient to abrogate this effect. These data suggest an important
and novel mechanism by which 5-Aza-dC and SAHA mediate
their effects on cell growth and apoptosis in pancreatic CSCs.
Figure 2. Chromatin modulators inhibit cell viability and promote apoptosis in pancreatic cancer stem cells on restoration of miR-
34a. (A), Pancreatic CSCs were treated with SAHA (3 and 5 mM) and 5-Aza-dC (2 and 4 mM) and cell viability was measured at 48 h by staining with
trypan blue using Vi-CELL analyzer (Beckman Counter). (B), Pancreatic CSCs were untreated (a) or treated with SAHA (b) or 5Aza-dC (c) for 48 h, and
apoptosis was measured by staining with annexin-PI using Accuri Flow Cytometer. (C), Caspase-3/7 activity was measured in pancreatic CSCs treated
with SAHA (0.5 and 2 mM) or 5-Aza-dC (1 and 3 mM) for 24 h. Data represent mean 6 SD. * and $ = significantly different from control, P,0.05.
doi:10.1371/journal.pone.0024099.g002
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regulation of miR34a, we next examined the effects of 5-Aza-dC
on VEGF-B 39UTR-luciferase reporter activity (Fig. 4C). 5-Aza-
dC inhibited VEGF-B 39UTR-luciferase reporter activity in a
dose-dependent manner. By comparison, anti-miR34a blocked the
inhibitory effects of 5-Aza-dC on luciferase activity. Since SAHA
inhibited the expression of VEGF through up-regulation of
miR34a, we also examined the effects of SAHA on VEGF-B
39UTR-luciferase reporter activity. As demonstrated in Fig. 4D,
SAHA inhibited the VEGF-B 39UTR-Luciferase activity in a
dose-dependent manner. By comparison, anti-miR34a blocked the
inhibitory effects of SAHA on luciferase activity. These data
suggest that up-regulation of miR-34a by 5-Aza-dC and SAHA
may have functional significance on the regulation of Notch and
self-renewal.
Effect of miR-34a restoration on expression of stem cell
renewal genes
Notch signaling has been shown to play a role in the stem cell
renewal and cell fate determination in neural, hematopoietic and
embryonic stem cells [38]. Jagged 1 expression on progenitor cells
induces self renewal of stem cells due to Notch signaling activation
[39]. Notch receptors, ligands as well as downstream targets have
been identified to be upregulated in preneoplastic lesions to
invasive pancreatic cancers in human and mice, suggesting that
Notch signaling may be an early event leading to accumulation of
undifferentiated precursor cells in pancreatic cancer. We demon-
strate that re-enforced expression of miR-34a in pancreatic CSCs
upon treatment with SAHA, causes an inhibition in the mRNA
expression of all the components of Notch pathway, Notch
receptor Notch1, Notch 3 and its ligand Jagged1 and downstream
Notch target gene Hes1 expression (Fig. 5A). Down regulation of
Notch may thus contribute to the inhibition of stem cell renewal
and the invasive capacity of pancreatic CSCs.
Since SAHA inhibited the expression of several components of
the Notch pathway, we next measured the RBP-Jk reporter
activity by luciferase assay (Fig. 5B). SAHA inhibited the RBP-Jk-
Luciferase activity in a dose-dependent manner. By comparison,
anti-miR34a blocked the inhibitory effects of SAHA on RBP-Jk-
luciferase activity. These data suggest that up-regulation of miR-
34a by SAHA may have functional significance on the regulation
of VEGF.
Effect of miR-34a restoration on epithelial-mesenchymal
transition of pancreatic CSCs
EMT induction in cancer cells results in the acquisition of
invasive and metastatic properties [40]. We therefore investigated
the role of miR-34a restoration in the EMT regulation in
pancreatic CSCs. Zeb-1 is a crucial EMT activator and suppresses
the expression of basement membrane components and cell
Figure 3. Expression of putative targets of miR-34a. (A), Pancreatic CSCs were treated with or without SAHA for 48 h. The expression of
acetylated-p53, p21, PUMA, SIRT1, CDK6, CyclinD1, survivin and Bcl-2 was measured by the Western blot analysis. b-actin was used as a loading
control. (B), Pancreatic CSCs were treated with or without 5Aza-dC for 48 h. The expression of p21, PUMA, Notch 3, CDK6, survivin and Bcl-2 was
measured by the Western blot analysis. b-actin was used as a loading control. (C), SIRT1 39UTR-Luciferase activity. Pancreatic CSCs were transduced
with either SIRT1 39UTR-Luc construct or SIRT1 mutant 39UTR-Luc construct, and treated with SAHA (0–3 mM) for 24 h. Luciferase activity was
measured as per manufacturer’s instructions (Promega). Data represent mean 6 SD. *, # or % = significantly different from control, P,0.05.
doi:10.1371/journal.pone.0024099.g003
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transcription was significantly inhibited in pancreatic CSCs and
cancer cell lines upon treatment with SAHA (Fig. 6A and B). We
next investigated the effect of SAHA on the expression of other
EMT transcription factors Snail and Slug in pancreatic CSCs.
Taken together, SAHA resulted in inhibition of Snail, Slug and
Zeb1 transcription (Fig. 6B), thereby suggesting a role of miR-34a
in the reversal of the EMT transition in pancreatic CSCs.
Interestingly, 5-Aza-dC also inhibited the transcription of Slug
(data not shown), which may possibly play a role in inhibition of
invasion.
Since SAHA inhibited the expression of Zeb-1 through up-
regulation of miR34a, we also examined the effects of SAHA on
Zeb1 39UTR-luciferase reporter activity. As demonstrated in
Fig. 6C, SAHA inhibited Zeb-1 39UTR-Luciferase activity in a
dose-dependent manner. By comparison, anti-miR34a blocked the
inhibitory effects of SAHA on Zeb-1 39UTR-Luciferase activity.
These data suggest that up-regulation of miR-34a by SAHA may
havefunctionalsignificanceonEMT regulation byinhibitingZeb-1.
Cadherin switch has been shown to occur during EMT
regulation. Treatment of pancreatic CSCs with SAHA and 5-
Aza-dC alone induced the expression of E-Cadherin and inhibited
the expression of N-Cadherin, thereby showing that miR-34a is a
strong inducer of an epithelial phenotype (Fig. 6D).
5-Aza-dC and SAHA inhibit migration, colony formation,
invasion and spheroid formation
To further understand the effect of up-regulation of miR-34a
expression on the invasive potential of pancreatic CSCs, we next
investigated the effect of 5-Aza-dC and SAHA on the pancreatic
CSCs using scratch migration, soft agar colony formation, and
transwell boyden chamber invasion assays. Representative micro-
photographs of cells invading through scratch generated for the
control and 5-Aza-dC and SAHA treated pancreatic CSCs
showed significantly less migration in the treated group panel as
compared to control group (Fig. 7A).
>5-Aza-dC and SAHA reduced the ability of pancreatic CSCs
to form soft agar colonies as compared to control (Fig. 7B) and
transfection with anti-miR-34a nullified the effects of 5-Aza-dC
and SAHA on colony formation (data not shown). Invasion of
pancreatic CSCs through the matrigel coated membrane showed
that the number of invading cells was significantly inhibited in 5-
Aza-dC and SAHA treated cells and was approximately 75% less
than the number of cells invading in the control group (Fig. 7C).
Further, 5-Aza-dC and SAHA inhibited the spheroid formation in
pancreatic CSCs as seen in Fig. 7D. These results demonstrate
that miR-34a might play an important role in the regulation of
pancreatic tumorigenesis by inhibiting the self-renewal capacity of
pancreatic CSCs, metastasis and invasion.
Figure 4. Expression of putative targets of miR-34a. (A), Pancreatic CSCs were transiently transfected with either negative control (scrambled)
or anti-miR34a oligonucleotide and treated with Aza-5dC (4 mM) for 48 h. Western blot analysis was performed to measure the expression of cyclin
D1, CDK2, p27 and VEGF. b-actin was used as a loading control. (B), Pancreatic CSCs were transiently transfected with either negative control
(scrambled) or anti-miR34a oligonucleotide and treated with SAHA (3 mM) for 48 h. Western blot analysis was performed to measure the expression
of cyclin D1, CDK2, p27 and VEGF. b-actin was used as a loading control. (C), Regulation of VEGF-B 39UTR-Luciferase activity by Aza-5dC. Pancreatic
CSCs were transfected with either negative control (scrambled) or anti-miR34a oligonucleotides along with VEGF-B 39UTR-LUC construct, and treated
with Aza-5dC (0–3 mM) for 24 h. Luciferase activity was measured as per manufacturer’s instructions (Promega). Data represent mean 6 SD. *, @ or #
= significantly different from control, P,0.05. (D), Regulation of VEGF-B 39UTR-Luciferase activity. Pancreatic CSCs were transfected with either
negative control (scrambled) or anti-miR34a oligonucleotides along with VEGF-B 39UTR-LUC construct, and treated with SAHA (0–3 mM) for 24 h.
Luciferase activity was measured as per manufacturer’s instructions (Promega). Data represent mean 6 SD. *, @, # = significantly different from
control, P,0.05.
doi:10.1371/journal.pone.0024099.g004
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MicroRNAs (miRNAs) are small non-coding RNAs that
regulate the expression of other genes by transcriptional inhibition
or translational repression. Accumulating evidence suggests a role
for microRNAs in human carcinogenesis as novel types of tumor
suppressors or oncogenes [41,42]. Recently, miR-34a family
members were found to be directly regulated by TP53, and the
functional activity of miR-34a indicated a potential role as a tumor
suppressor. We demonstrate in this study that miR-34a expression
is down regulated in human pancreatic CSCs and pancreatic
tumor derived cell lines, irrespective of their p53 mutational status.
5Aza-dC and SAHA can epigenetically restore the expression of
miR-34a independent of the p53 mutational status in pancreatic
cancer. Furthermore, miR-34a inhibits SIRT1 expression through
a miR-34a-binding site within the 39 UTR of SIRT1. This finding
substantiates our hypothesis that miR-34a may be thus epigenet-
ically regulated in pancreatic cancer.
DNA methylation is involved in regulating normal biologic
processes as well as carcinogenesis. DNA methylation is a heritable
modification of the DNA structure, which do not alter the specific
sequence of base pairs responsible for encoding the genome, but
which can directly inhibit gene expression. Hypomethylating
agents (azacitidine and decitabine) and Histone deactylase
(HDAC) inhibitors suberoylanilide hydroxamic acid (SAHA) have
been approved by FDA for the treatment of myelodydplastic
syndrome and cutaneous T cell lymphoma, respectively. Pre-
clinically and clinically these agents have also shown to sensitize
cancer cells to chemotherapeutic agents and biologically targeted
drugs [43,44]. Novel therapeutic regimens can be developed by
modulating histone acetylation along with other therapeutic
strategies such as inhibition of DNA methylation, intracellular
signal transduction pathway and transcription factors as well as
induction of apoptosis.
Our data reveal that the chromatin modulators, 5Aza-dC and
SAHA can epigenetically restore the expression of miR-34a
independent of the p53 mutational status in pancreatic CSCs and
pancreatic cancer tumor derived cell lines. These chromatin
modifying agents can also regulate the downstream targets of miR-
34a, thus suggesting the role of miR-34a restoration in regulating
the pancreatic tumorigenesis and providing a functional basis for
the epigenetic inactivation of this miRNA in pancreatic cancer.
Another plausible explanation of this could be that in addition to
the epigenetic silencing of miR-34a, SIRT1 a downstream target
of miR-34a may be a key player through a SIRT1-p53 pathway.
SIRT1 is up regulated in pancreatic cancer, which is a NAD
dependent deactylase and has been shown to inhibit several pro-
apoptotic genes. SIRT1 inactivates p53 by deacetylation of p53
[45]. miR-34a is itself a transcriptional target of p53 suggesting a
positive feedback between p53 and miR-34a. SAHA down
Figure 5. Inhibtion of self-renewal genes that are targets of miR-34a in pancreatic CSCs. (A), Pancreatic CSCs were treated with SAHA (1
and 3 mM) for 24 h, and the expression of Notch1, JAGGED1, NOTCH3 and HES1 was measured by qRT-PCR. Data represent mean 6 SD. * or $ =
significantly different from control, P,0.05. (B), RBP-Jk reporter activity. Pancreatic CSCs were transfected with either negative control (scrambled) or
anti-miR34a oligonucleotides along with RBP-Jk-LUC construct, and treated with SAHA (0–3 mM) for 24 h. Luciferase activity was measured as per
manufacturer’s instructions (Promega). Data represent mean 6 SD. *, # or @ = significantly different from control, P,0.05.
doi:10.1371/journal.pone.0024099.g005
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34a, which can now participate in a positive feedback loop leading
to further activation of p53. The microRNA mediated feed
forward loop stabilizes p53 through acetylation, leading to
increased transcriptional activity of p53, thus promoting apoptosis.
This is represented from our data, which shows induction of
acetylated p53 and its transcriptional targets p21
WAF1 and PUMA
that regulate the cell cycle and apoptosis, upon treatment with
SAHA. Thus it explains how epigenetic silencing of miR-34a
would interrupt this feedback, resulting in lower p53 activity,
thereby providing a selective advantage to the pancreatic cancer
cells. These observations are in concert with published studies of
Yamakuchi et al [46], where they have shown that p53 acetylation
on lysine 382 is increased after ectopic miR-34a expression and
also by Fujita et al who have reported the down-regulation of
SIRT1 by miR-34a [47].
Deregulated Notch signaling is associated with pancreatic
tumorigenesis [48,49] and cell invasion [50]. Up regulation of
Zeb-1 and Jagged 1 has been associated with the aggressiveness of
pancreatic adenocarcinoma resulting in increased Notch signaling
[39]. We have demonstrated here that re-expression of miR-34a in
pancreatic cancer stem cells on treatment with SAHA, causes an
inhibition in the mRNA expression of all the components of Notch
pathway. Down regulation of Notch contributes to the inhibition
and apoptosis of pancreatic CSCs. Interestingly, SAHA also
inhibited the expression of VEGF thus suggesting that by
inhibiting the Notch pathway, miR-34a may play an anti-
angiogenic and anti-invasive role as well. Restoration of miR-
34a expression in pancreatic CSCs by the chromatin modifiers
significantly reduced in vitro migration, invasion and anchorage-
independent growth.
In conclusion, we demonstrate that miR-34a is a tumor
suppressor gene which targets multiple critical oncogenic pathways.
The restoration of miR-34a by pharmacological intervention thus
provide novel prospects for clinical innovation laying the ground
work for in vivo experiments in the future. The effect of these
chromatin modulators on xeno-transplants of pancreatic CSCs in
micewillprovideuswithaninsightofthefutureoftumorsuppressor
miRNAs restorations and their physiological significance.
Methods
Reagents
Antibodies against p21
/WAF1/CIP1, p27
/KIP1, cyclin D1, CDK2,
CDK4 and CDK6 were purchased from Cell Signaling Technol-
ogy, Inc. (Danvers, MA). Antibodies against Bcl-2, SIRT1, VEGF,
acetylated and total p53 and PUMA and b-actin were purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). 5-Aza-dC
was purchased from Calbiochem. SAHA was obtained from the
National Cancer Institute. Penicillin, streptomycin, RPMI-1640
medium, Keratinocyte and fetal bovine serum (FBS) were
obtained from Invitrogen Corporation (Carlsbad, CA). Tris-HCl,
glycine, sodium chloride, sodium dodecyl sulfate (SDS) and bovine
serum albumin (BSA) were obtained from Sigma-Aldrich (St.
Louis, MO). Annexin-V-FITC/propidium iodide (PI) kit was
purchased from BD Biosciences (San Jose, CA). Enhanced
chemiluminescence (ECL) Western blot detection reagents were
from Amersham Life Sciences Inc. (Arlington Heights, IL).
Figure 6. Role of miR-34a restoration on the EMT regulation in pancreatic cancer cells and CSCs. (A), Pancreatic cancer cell lines [ASPC-
1(p53wt) and MiaPACA-2 (p53mutant)] and pancreatic CSCs were treated with SAHA (1 mM) for 24 h, and the expression of Zeb1 was measured by
qRT-PCR. Data represent mean 6 SD. * = significantly different from control, P,0.05. (B), Pancreatic CSCs were treated with SAHA (1 mM) for 24 h
and the expression of Snail, Slug and Zeb1 was measured by qRT-PCR. HK-GAPD was used as the endogenous normalization control. Data represent
mean 6 SD. * = significantly different from control, P,0.05. (C), Regulation of Zeb-1 39UTR reporter activity. Pancreatic CSCs were transfected with
either negative control (scrambled) or anti-miR34a oligonucleotides along with Zeb1 39UTR-Luciferase construct, and treated with SAHA (0–3 mM) for
24 h. Luciferase activity was measured as per manufacturer’s instructions (Promega). Data represent mean 6 SD. *, #, % = significantly different
from control, P,0.05. (D), Pancreatic CSCs were treated with SAHA (1 mM) or 5-Aza-dC (2 mM) for 24 h and the expression of E-cadherin and N-
cadherin was measured by qRT-PCR. Data represent mean 6 SD. * = significantly different from control, P,0.05.
doi:10.1371/journal.pone.0024099.g006
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MIA PaCa-2 and AsPC-1 cells were obtained from the
American Type Culture Collection (Manassas, VA). Human
pancreatic CSCs (CD44+/CD24+/ESA+) have been character-
ized and described previously [17]. CSCs were cultured in DMEM
supplemented with 1% N2 Supplement (Invitrogen), 2% B27
Supplement (Invitrogen), 20 ng/ml human platelet growth factor
(Sigma-Aldrich), 100 ng/ml epidermal growth factor (Invitrogen)
and 1% antibiotic-antimycotic (Invitrogen) at 37uC in a humid-
ified atmosphere of 95% air and 5% CO2.
Isolation of RNA
The total RNA was isolated from the pancreatic cancer stem
cells and pancreatic cell lines using TRIzol (Life Technologies)
according to the manufacturer’s instructions. The RNA pellets
were then frozen and stored at 280uC until use.
Evaluation of miRNAs and mRNA expression levels by
quantitative real time-PCR
qRT-PCR of microRNAs was performed using TaqMan
microRNA assays (Applied Biosystems) in an Applied Biosystems
7300 Sequence Detection System (Applied Biosystems, Foster
City, CA). Ten nanograms of total RNA were reverse transcribed
using a TaqManH MicroRNA Reverse Transcription (RT) kit
from Applied Biosystems. Each RT reaction contained 1x stem-
loop RT specific primer, 1x reaction buffer, 0.25 mM each of
dNTPs, 3.33 U/ml Multiscribe RT enzyme and 0.25 U/ml
RNase inhibitor. The 15-ml reactions were incubated for
30 min at 16uC, 30 min at 42uC, and 5 min at 85uC and then
held at 4uC. The PCR reaction was performed using a standard
TaqManH PCR kit protocol (Applied Biosystems). Briefly,
following the RT step, 1.33 ml of the RT reaction were
combined with 1 ml of a TaqMAn MicroRNA Assay (20x;
forward primer, reverse primer and probe) and 17.67 mlo f
TaqManH Universal PCR Master Mix, No AmpEraseH UNG in
a2 0ml final volume. The reactions were incubated at 95uCf o r
10 min, followed by 40 cycles of 95uC for 15 s and 60uCf o r
1 min. The expression of miR-34a was normalized against the
expression of another small RNA, RNU48 as endogenous
normalization control. All assays were performed in triplicate
and were calculated on the basis of DDCt method. The n-fold
change in miRNAs expression was determined according to the
method of 2
2DDCT.
For the quantification of gene amplification, Real-time PCR
was performed using an ABI 7300 Sequence Detection System in
the presence of SYBR- Green. Briefly, RNA isolated with or
without treatment with the chromatin modifiers using TRIzol (Life
Technologies) were reverse transcribed. cDNA reactions were
amplified with QPCR SYBR Green Mix (Applied Biosystems) and
the following gene-specific primers:
NOTCH 1 (59- gga cct cat caa ctc aca cg -39,5 9- ggt gtc tcc tcc
ctg ttg tt -39)
Figure 7. SAHA and 5-Aza-dC inhibit migration, colony formation, invasion and spheroid formation. (A), Photomicrographs
demonstrating the results of the in vitro migration of pancreatic CSCs using the simple scratch technique. Pancreatic CSCs were grown in monolayer,
scratched and treated with SAHA and 5-Aza-dC for 24 h. (B), SAHA and 5-Aza-dC inhibit colony formation by CSCs. Pancreatic CSCs were seeded in
soft agar and treated with SAHA (1 and 3 mM) or 5-Aza-dC (2 and 4 mM) for 21 days. At the end of incubation period, colonies were counted. Data
represent mean 6 SD. * and $ = significantly different from control, P,0.05. (C), CSCs were plated onto the Matrigel-coated membrane in the top
chamber of the transwell and treated with SAHA (1 and 3 mM) or 5-Aza-dC (2 and 4 mM) for 48 hrs. Cells invaded to the lower chambered were fixed
with methanol, stained and photographed. (D), Pancreatic CSCs were seeded in suspension and treated with SAHA (1 and 3 mM) or Aza-5dC (2 and
4 mM) for 7 days. Pictures of spheroids formed in suspension were taken by a microscope.
doi:10.1371/journal.pone.0024099.g007
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agg gac ac -39)
JAG (59- ggc ctc tga aga aca gaa ca -39,5 9- ttt ctc aat ggg gtt ttt
ga -39)
HES1 (59- acc aaa gac agc atc tga gc -39,5 9- ggt gct tca ctg tca
ttt cc -39)
SNAIL (59- acc cca cat cct tct cac tg -39,5 9- tac aaa aac cca cgc
aga ca -39)
SLUG (59- aca cac aca cac cca cag ag -39,5 9- aaa tga ttt ggc agc
aat gt -39)
ZEB1 (59- gca caa cca agt gca gaa ga -39,5 9- cat ttg cag att gag
gct ga -39)
E- CADHERIN (59- tgc tct tgc tgt ttc ttc gg-39,5 9- tgc ccc att cgt
tca agt ag-39)
N- CADHERIN (59- tgg atg gac ctt atg ttg ct -39,5 9- aac acc tgt
ctt ggg atc aa -39)
GAPDH (59- gag tca acg gat ttg gtc gt -39,5 9- ttg att ttg gag gga
tct cg -39)
Target sequences were amplified using incubated at 95uC for
10 min, followed by 40 cycles of 95uC for 15 s and 60uC for
1 min. HK-GAPD is used as endogenous normalization control.
All assays were performed in triplicate and were calculated on the
basis of DDCt method. The n-fold change in miRNAs expression
was determined according to the method of 2
2DDCT.
Transfecting cells with pre-miRs
TM and anti-miRs
Enhanced or knockdown expressions of miR-34a were per-
formed by transfection with miR-34a precursor (Ambion) or anti-
miR-34a (Ambion), respectively. All transfections were carried out
in triplicate. 50 nmol of pre-miR
TM, anti-miR and Negative-
control pre and anti-miR 34a (Ambion), respectively, were
transfected using lipofectamine 2000 (Invitrogen) for 24 h.
Twenty-four hours following transfection the cells were treated
in presence or absence of 5-Aza-dC or SAHA and the Total-RNA
and Protein were isolated 48 hours post treatment.
Lentiviral reporter assay
The cop-GFP and luciferase genes were cloned downstream of
CSL/RBP-Jk-response element, containing four CSL/RBP-Jk
binding motifs (pGreen Fire1-4xNotch-mCMV-EF1-Neo; System
Biosciences, Mountain View, CA). For in vitro assays, stably
transduced pancreatic CSCs were plated at 5–10,000 cells per well
in 24-well plates and treated with various doses of drugs. After
incubation, CSCs were analyzed for either GFP expression by
fluorometer or luciferase activity by luminometer. Other reporter
assays were performed in a similar manner.
Viral production and infection
For lentiviral particle production, HEK 293T cells were
transduced with plasmids of interest in the presence of lipofecta-
mine. Viral supernatants were collected, mixed with PEG and
concentrated by ultracentrifugation to produce virus stocks with
titers of 1610
8 to 1610
9 infectious units per milliliter. Viral
supernatant was collected for three days by ultracentrifugation and
concentrated 100-fold. Titers were determined on HEK293T
cells. Human pancreatic CSCs were transduced with a mixture of
viral particles and polybrene with two rounds of infections.
Measurement of apoptosis
Early apoptotic process is characterized by changes in the
phospholipid bilayers of cell membranes. The phosphotidylserine
(PS) component of the phospholipid bilayers are externalized and
can be detected by fluorescence labeling. Annexin V is a member
of the annexin family of calcium-dependent phospholipid-binding
proteins which has a high affinity for PS-containing phospholipid
bilayers. Staining with FITC-conjugated annexin V and propi-
dium iodide (PI) can help quantitate subpopulations of cells with
compromised membrane integrity. Untreated control and treated
cells were washed twice with cold PBS and resuspended in buffer
at a concentration of 10
6 per ml. Cells were mixed with 10 mlo f
fluoresceine isothiocyanate (FITC)-conjugated annexin V reagent
and 10 ml of 3 mM propidium iodide (PI). After a 15 min
incubation at room temperature in the dark and further washings,
samples were analysed by flow cytometry. Flow cytometry was
performed with a FACScan analyzer (Becton Dickinson) with
15 mW argon ion laser (488 nm) and Cell Quest software.
Annexin V staining was detected in the FL1 (green) channel,
whereas PI staining was monitored in the FL2 (red) channel:
appropriate quadrants were set and the percentage of cells
negative for both stains (viable cells), positive for annexin V
(apoptotic cells) and positive for PI (dead cells) were acquired.
Cell cycle distribution analysis
Cell cycle distribution and ploidy status of pancreatic cancer
cells after treatment with Aza-5-dC and SAHA and untreated
controls were determined by flow cytometry DNA analysis as
described previously [51,52] . Briefly at the end of treatments, cells
were detached from the plates by the addition of 0.25% trypsin,
washed in PBS, fixed in 70% ethanol at 4uC and treated with
10 mg/ml RNAse for 30 min at 37uC. The DNA content was
evaluated in a FACScan flow cytometer (Becton-Dickson, NJ,
USA) after staining cells with propidium iodide buffer (0.1 mM
EDTA, 0.1% Triton X-100, 50 mg/ml propidium iodide, PBS
pH 7.4) for 15 min in the dark at room temperature. For cell cycle
analysis, only single cells were considered. A pass filter of 585 nm
was used to collect PI fluorescence, acquiring 10,000 events for
each sample.
Caspase-3/7 assay
Pancreatic cancer stem cells (36104 per well) were seeded in a
96-well plate with 200 ml culture medium. Approximately 16 h
later, cells were treated with and without various doses of 5Aza-dC
and SAHA. Casapse-3/7 activity was measured by a fluorometer
as per manufacturer’s instructions (Invitrogen).
Western blot analysis
At the end of treatments with Aza-5-dC and SAHA, as well as
untreated control were analyzed using western blot analysis as
described before [17]. Breifly, cells were washed with cold PBS
and lysed in ice-cold lysis buffer (50 mM Tris-HCl pH 7.5, 2 mM
EDTA, 2 mM EGTA, 10 mM b-glycerophosphate, 150 mM
NaCl, 0.5% NP-40, 1 mM phenyl-methyl sulfonyl fluoride, 1 mM
NaF, 1 mM DTT, 1% b-mercaptoethanol and 4 mg/ml complete
protease inhibitor cocktail (EMD Biosciences). Cell lysates were
centrifuged at 15,000 g for 15 min at 4uC and protein concen-
tration was determined in the supernatants using the Coomassie
Plus protein assay reagent (Pierce, Rockford, IL) using bovine
serum albumin as standard. About 40 mg of crude proteins were
mixed with SDS sample buffer, denatured and electrophoresed in
12% SDS-PAGE gels. After electrophoresis, gels were transferred
to nitrocellulose membranes by electroblotting and blocked for two
h at room temperature in TBST (50 mM Tris-HCl pH 7.5,
150 mM NaCl, 0.2% Tween-20) containing 5% nonfat milk. Blots
were sequentially incubated with the primary and secondary
antibodies, washed in TBS-T. Membranes were developed by
enhanced chemiluminescence (ECL-Plus, Amersham Pharmacia
Biotech, Piscataway, NJ) and exposed to Kodak Biomax Light
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were stripped by incubation with 100 mM Tris-HCl, pH 7.4,
100 mM b-mercaptoethanol, and 2% SDS at 60uC for 30 min.
Motility assay
Scratch migration assay was used to study the horizontal
movement of cells. A confluent monolayer of cells was established
and then a scratch is made through the monolayer, using a
standard 1–200 ml plastic pipet tip, which gives rise to an in vitro
wound, washed twice with PBS, and replaced in media with or
without chromatin modifying agents. Cancer stem cells migrate
into the scratch area as single cells from the confluent sides. The
width of the scratch gap is viewed under the microscope in four
separate areas each day until the gap is completely filled in the
untreated control wells. Three replicate wells from a 6-well plate
were used for each experimental condition.
To quantitate vertical motility, an in vitro transwell invasion
assay was used. In this assay, 1610
5 cells were plated in the top
chamber onto the Matrigel coated Membrane (24-well insert; pore
size, 8 mm; Corning Costar). Each well was coated freshly with
Matrigel (60 mg; BD Bioscience) before the invasion assay. Cells
were plated in complete medium and medium supplemented with
chromatin modifying agents was used in the lower chamber. The
cells were incubated for 48 hours and cells that did not invade
through the pores were removed by a cotton swab. Cells on the
lower surface of the membrane were fixed with methanol and
stained with crystal violet. The number of cells invading through
the membrane was counted under a light microscope (40X, three
random fields per well).
Soft agar colony assay for assessment of tumorigenic
potential in vitro
To examine the anchorage independent growth, the pancreatic
cancer stem cells derived from primary human tumors were
suspended (10
3 cells/ml) in 2 ml of 0.3% agar with 1% N2
Supplement (Invitrogen), 2% B27 Supplement (Invitrogen),
20 ng/ml human platelet growth factor (Sigma-Aldrich),
100 ng/ml epidermal growth factor (Invitrogen) and 1% antibi-
otic-antimycotic (Invitrogen) overlaid into six-well plates contain-
ing a 0.5% agar base. All samples were plated in triplicate.
Colonies with .0.2 mm in diameter were counted on day 21.
Colonies were stained with 0.001% crystal violet blue and
counted.
Statistical analysis
The mean and standard deviation (SD) were calculated for each
experimental group. Differences between groups were analyzed by
one or two way ANOVA using PRISM statistical analysis software
(GrafPad Software, Inc., San Diego, CA). Significant differences
among groups were calculated at P,0.05.
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